



GENNEX LABORATORIES LIMITED

CIN : L24230TG1990PLC011168

Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,
Dist : Sangareddy, Telangana - 502 325. INDIA

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2022

(Rs. In Lacs)

S No.	PARTICULARS	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income								
	Revenue from Operations	1,393.73	2,017.80	1,037.29	6,121.38	1,393.73	2,017.80	1,037.29	6,121.38
	Other Income	57.36	104.32	2.57	138.14	57.36	104.32	2.57	138.14
	Total Income	1,451.09	2,122.12	1,039.86	6,259.52	1,451.09	2,122.12	1,039.86	6,259.52
2	Expenses								
(a)	Cost of material consumed	1,240.42	1,348.91	650.36	4,001.04	1,240.42	1,348.91	650.36	4,001.04
(b)	Purchase of stock-in-trade	-	-	-	-	-	-	-	-
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	-423.22	-65.47	-123.18	-190.72	-423.22	-65.47	-123.18	-190.72
(d)	Employees Cost	185.86	206.64	166.18	696.86	185.86	206.64	166.18	696.86
(e)	Depreciation	17.89	34.24	20.19	78.85	17.89	34.24	20.19	78.85
(f)	Finance Cost	26.40	19.59	15.27	87.74	26.40	19.59	15.27	87.74
(g)	Other Expenses	303.09	449.76	180.82	1,076.40	303.09	449.76	180.82	1,076.40
	Total Expenses	1,350.44	1,993.67	909.63	5,750.17	1,350.44	1,993.67	909.63	5,750.17
3	Total Profit before exceptional Items & Tax.	100.65	128.45	130.23	509.35	100.65	128.45	130.23	509.35
4	Exceptional items	-	-	-	-	-	-	-	-
5	Total profit before tax	100.65	128.45	130.23	509.35	100.65	128.45	130.23	509.35
6	Tax expense for earlier years	-	-	-	-	-	-	-	-
	Curent tax	-25.33	-36.12	-34.80	-132.00	-25.33	-36.12	-34.80	-132.00
	Deferred Tax	-	14.97	-	14.97	-	14.97	-	14.97
	Total Tax Expenses	-25.33	-21.15	-34.80	-117.03	-25.33	-21.15	-34.80	-117.03
7	Net profit /(Loss)	75.32	107.30	95.43	392.32	75.32	107.30	95.43	392.32
8	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-	-	-
9	Total Profit (losss) for period	75.32	107.30	95.43	392.32	75.32	107.30	95.43	392.32
10	Other comprehensive income net of taxes		18.22		18.22		18.22		18.22
11	Total Comprehensive income for the period Total profit or loss, attributable to Profit or loss, attributable to owners of parent		125.52		410.54		125.52		410.54
12	Total Comprehensive income for the period attributable to Comprehensive income for the period attributable to owners of parent								
13	Total comprehensive income for the period attributable to owners of parent non controlling interests								
14	Details of equity share capital								
	Paid up equity share capital	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03
	Face value of equity share capital	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001
15	Earnings per share								
	- Basic	0.060	0.099	0.075	0.325	0.060	0.099	0.075	0.325
	- Diluted	0.060	0.099	0.075	0.325	0.060	0.099	0.075	0.325

Notes to the results:

- 1 The above unaudited financial results have been reviewed by the Audit Committee of it meeting held on 12.08.2022 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- 2 The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2022.
- 3 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 4 The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs,Biotech Products and Intermediates".Previous period's figures have been rearranged/regrouped wherever necessary.
- 5 Adjustment of actuarial valuation in respect of compliance with Accounting Standard- IAS-19-'Employee Benefits' is to be done at the year end.
- 6 The quarterly unaudited financial results for the Quarter ended June 30, 2022 are available on the Company's Website i.e;www.gennexlab.com and also available on BSE website i.e; www.bseindia.com.

**For and on behalf of the Board
For Gennex Laboratories Limited**

Place: Hyderabad
Date: 12.08.2022

T.M.Gopalakrishnan
Whole Time Director
DIN # 03137458